scholarly journals Silencing of EEF2K (eukaryotic elongation factor-2 kinase) reveals AMPK-ULK1-dependent autophagy in colon cancer cells

Autophagy ◽  
2014 ◽  
Vol 10 (9) ◽  
pp. 1495-1508 ◽  
Author(s):  
Chuan-Ming Xie ◽  
Xiao-Yu Liu ◽  
Kathy WY Sham ◽  
Josie MY Lai ◽  
Christopher HK Cheng
Keyword(s):  
Colon Cancer ◽  
Cancer Cells ◽  
Elongation Factor ◽  
Colon Cancer Cells ◽  
Elongation Factor 2 ◽  
Eukaryotic Elongation Factor 2 ◽  
Eukaryotic Elongation Factor

scholarly journals Progress in the Development of Eukaryotic Elongation Factor 2 Kinase (eEF2K) Natural Product and Synthetic Small Molecule Inhibitors for Cancer Chemotherapy

2021 ◽  
Vol 22 (5) ◽  
pp. 2408
Author(s):  
Bin Zhang ◽  
Jiamei Zou ◽  
Qiting Zhang ◽  
Ze Wang ◽  
Ning Wang ◽  
...  
Keyword(s):  
Cancer Cells ◽  
Elongation Factor ◽  
Cancer Drug ◽  
Discovery Research ◽  
Elongation Factor 2 ◽  
Eukaryotic Elongation Factor 2 ◽  
Eukaryotic Elongation Factor ◽  
Drug Discovery Research ◽  
Anti Cancer

Eukaryotic elongation factor 2 kinase (eEF2K or Ca2+/calmodulin-dependent protein kinase, CAMKIII) is a new member of an atypical α-kinase family different from conventional protein kinases that is now considered as a potential target for the treatment of cancer. This protein regulates the phosphorylation of eukaryotic elongation factor 2 (eEF2) to restrain activity and inhibit the elongation stage of protein synthesis. Mounting evidence shows that eEF2K regulates the cell cycle, autophagy, apoptosis, angiogenesis, invasion, and metastasis in several types of cancers. The expression of eEF2K promotes survival of cancer cells, and the level of this protein is increased in many cancer cells to adapt them to the microenvironment conditions including hypoxia, nutrient depletion, and acidosis. The physiological function of eEF2K and its role in the development and progression of cancer are here reviewed in detail. In addition, a summary of progress for in vitro eEF2K inhibitors from anti-cancer drug discovery research in recent years, along with their structure–activity relationships (SARs) and synthetic routes or natural sources, is also described. Special attention is given to those inhibitors that have been already validated in vivo, with the overall aim to provide reference context for the further development of new first-in-class anti-cancer drugs that target eEF2K.

scholarly journals Eukaryotic elongation factor 2 kinase confers tolerance to stress conditions in cancer cells

2014 ◽  
Vol 20 (2) ◽  
pp. 217-220 ◽  
Author(s):  
Hongcheng Zhu ◽  
Xi Yang ◽  
Jia Liu ◽  
Lu Zhou ◽  
Chi Zhang ◽  
...  
Keyword(s):  
Cancer Cells ◽  
Elongation Factor ◽  
Stress Conditions ◽  
Elongation Factor 2 ◽  
Eukaryotic Elongation Factor 2 ◽  
Eukaryotic Elongation Factor
Sign in / Sign up

Export Citation Format

Share Document